...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy.
【24h】

Treatment of T1-T2 rectal tumors by contact therapy and interstitial brachytherapy.

机译:通过接触疗法和间质近距离放射疗法治疗T1-T2直肠肿瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: We retrospectively analysed our experience of contact therapy alone and/or combined with interstitial brachytherapy as exclusive treatment of low lying rectal tumours. PATIENTS AND METHODS: From 1971 to 2001, 124 patients (103 adenocarcinomas, 21 villous tumours) were treated by contact therapy alone or combined with interstitial brachytherapy. All patients were staged according to the Dijon classification. The average size of the lesions was 2.4 cm (max 7 cm), clinical aspect was polypoid in 75% of the cases, flat in 17%. Sixty four patients received contact therapy in three fractions and 44 patients received four fractions, for an average delivered dose of 95 Gy. Interstitial brachytherapy boost delivered 24 Gy on a reference isodose of 55 cGy/h in 10 patients. RESULTS: The local control was 83% for T1 and 38% for T2 tumours (p=0.004). For mobile tumours, the local control rate is 76%, significantly higher than for tumours with impaired mobility (55%, P=0.03). Thirty-nine patients experienced a local failure (31%). For patients amenable to surgery, a Miles procedure was performed in 25 patients. Ultimate local control rate is 93% for T1, 69% for T2 (P<0.05), 15 patients failed despite treatment for local recurrence (15%). No significant differences were observed in a comparison of adenocarcinoma and villous tumours according to initial and ultimate local control. The mean disease free survival rate for the whole population is 66 months. The 5-year disease free survival for T1a and T1b is, respectively, 82 and 78%, 40 and 25% for T2a and T2b, respectively. The overall 5-year survival for the whole group is 62.4%. At the end of the treatment, 75% of the patients described a very good sphincter function. No deleterious effect on continence was reported during the follow-up. CONCLUSIONS: The control rate for T1 rectal cancer treated with contact therapy with or without brachytherapy is comparable to surgical series. The sphincter was preserved in 80% of the patients. Radiotherapy remains an efficient and cheap alternative to surgery, mainly for old and fragile patients, or refusing colostomy. The results of these approaches for tumors larger than 3 cm (T2) are not satisfactory. For patients not amenable to surgery, external beam radiation therapy and/or combined modality with chemoradiation should be discussed to increase the loco-regional control rate. A careful selection of patients based on rectal examination and trans-rectal ultrasound could select more accurately patients amenable to such an approach.
机译:背景与目的:我们回顾性分析了单独接触治疗和/或间质近距离放射治疗作为低位直肠肿瘤的独家治疗的经验。患者与方法:从1971年至2001年,仅通过接触疗法或间质近距离放射疗法治疗了124例患者(103例腺癌,21例绒毛状肿瘤)。所有患者均根据第戎分类分期。病变的平均大小为2.4厘米(最大7厘米),在75%的病例中临床表现为息肉样,在17%的病例中持平。 64名患者接受了三部分的接触治疗,而44名患者接受了四部分的接触治疗,平均递送剂量为95 Gy。间质近距离放射疗法在10名患者的55 cGy / h的参考等剂量剂量下可提供24 Gy的剂量。结果:T1肿瘤局部控制率为83%,T2肿瘤局部控制率为38%(p = 0.004)。对于活动性肿瘤,局部控制率为76%,显着高于活动性受损的肿瘤(55%,P = 0.03)。三十九名患者发生局部衰竭(31%)。对于适合手术的患者,对25例患者进行了Miles手术。 T1的最终局部控制率为93%,T2的最终局部控制率为69%(P <0.05),尽管进行了局部复发治疗,但仍有15例患者失败(15%)。根据初始和最终局部对照,在腺癌和绒毛状肿瘤的比较中未观察到显着差异。整个人群的平均无病生存期为66个月。 T1a和T1b的5年无病生存率分别为T2a和T2b的82%和78%,40%和25%。整个组的5年总生存率为62.4%。在治疗结束时,有75%的患者表现出很好的括约肌功能。随访期间未报告对节制有害。结论:采用或不采用近距离放射疗法的接触疗法治疗的T1直肠癌的控制率与外科手术系列相当。 80%的患者保留了括约肌。放射疗法仍然是手术的一种有效且廉价的替代方法,主要用于老年和脆弱患者,或拒绝结肠造口术。这些方法对大于3 cm(T2)的肿瘤的结果并不令人满意。对于不适合手术的患者,应讨论外部束放射治疗和/或化学放疗的联合方式以提高局部控制率。根据直肠检查和经直肠超声仔细选择患者,可以更准确地选择适合这种方法的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号